Niklason Laura E 4
4 · Humacyte, Inc. · Filed Jan 23, 2025
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Niklason Laura E
DirectorPresident, CEO and Director
Transactions
- Award
Stock Options (right to buy)
2025-01-21+1,130,311→ 1,130,311 totalExercise: $4.56Exp: 2035-01-21→ Common Stock (1,130,311 underlying)
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.